HC Wainwright reaffirmed their buy rating on shares of Stemline Therapeutics Inc. (NASDAQ:STML) in a research report released on Monday.

Several other equities research analysts have also recently commented on the company. Roth Capital reissued a buy rating and issued a $32.00 price target on shares of Stemline Therapeutics in a research note on Friday, November 11th. Zacks Investment Research cut Stemline Therapeutics from a hold rating to a sell rating in a research report on Friday, November 11th. Wedbush reaffirmed an outperform rating and set a $15.00 target price on shares of Stemline Therapeutics in a research report on Tuesday, November 8th. Finally, Jefferies Group reaffirmed a buy rating on shares of Stemline Therapeutics in a research report on Friday, August 5th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $20.50.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Stemline Therapeutics (NASDAQ:STML) opened at 13.40 on Monday. Stemline Therapeutics has a 12-month low of $3.88 and a 12-month high of $14.20. The firm’s market cap is $239.14 million. The firm has a 50-day moving average of $11.93 and a 200-day moving average of $8.77.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp raised its position in shares of Stemline Therapeutics by 1.9% in the second quarter. State Street Corp now owns 220,768 shares of the biopharmaceutical company’s stock worth $1,493,000 after buying an additional 4,197 shares during the last quarter. Rhumbline Advisers raised its position in shares of Stemline Therapeutics by 20.9% in the second quarter. Rhumbline Advisers now owns 26,260 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 4,538 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Stemline Therapeutics by 11.8% in the second quarter. Franklin Resources Inc. now owns 2,102,200 shares of the biopharmaceutical company’s stock worth $14,232,000 after buying an additional 222,170 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Stemline Therapeutics by 6.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 187,428 shares of the biopharmaceutical company’s stock worth $1,269,000 after buying an additional 11,292 shares during the last quarter. Finally, BlackRock Fund Advisors raised its position in shares of Stemline Therapeutics by 7.8% in the second quarter. BlackRock Fund Advisors now owns 438,016 shares of the biopharmaceutical company’s stock worth $2,965,000 after buying an additional 31,748 shares during the last quarter. Institutional investors and hedge funds own 49.23% of the company’s stock.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

5 Day Chart for NASDAQ:STML

Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.